ID24597A - Komposisi farmasi yang mengandung penghambat reduktase aldosa dan penghambat ace - Google Patents

Komposisi farmasi yang mengandung penghambat reduktase aldosa dan penghambat ace

Info

Publication number
ID24597A
ID24597A IDW991606A ID991606A ID24597A ID 24597 A ID24597 A ID 24597A ID W991606 A IDW991606 A ID W991606A ID 991606 A ID991606 A ID 991606A ID 24597 A ID24597 A ID 24597A
Authority
ID
Indonesia
Prior art keywords
ace
hazers
aldosa
pharmaceutical composition
contains reduction
Prior art date
Application number
IDW991606A
Other languages
English (en)
Inventor
Frank Carey
David Patrick Tuffin
Norman Eugene Cameron
Mary Anne Cotter
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of ID24597A publication Critical patent/ID24597A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IDW991606A 1997-07-08 1998-07-02 Komposisi farmasi yang mengandung penghambat reduktase aldosa dan penghambat ace ID24597A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9714274.9A GB9714274D0 (en) 1997-07-08 1997-07-08 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
ID24597A true ID24597A (id) 2000-07-27

Family

ID=10815469

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW991606A ID24597A (id) 1997-07-08 1998-07-02 Komposisi farmasi yang mengandung penghambat reduktase aldosa dan penghambat ace

Country Status (27)

Country Link
US (1) US6337327B1 (id)
EP (1) EP0991424B1 (id)
JP (1) JP2002509540A (id)
KR (1) KR20010015551A (id)
CN (1) CN1186097C (id)
AT (1) ATE205402T1 (id)
AU (1) AU746211B2 (id)
BR (1) BR9810570A (id)
CA (1) CA2292451A1 (id)
CZ (1) CZ290276B6 (id)
DE (1) DE69801661T2 (id)
DK (1) DK0991424T3 (id)
ES (1) ES2163283T3 (id)
GB (1) GB9714274D0 (id)
HU (1) HU224009B1 (id)
ID (1) ID24597A (id)
IL (1) IL133004A (id)
NO (1) NO20000045D0 (id)
NZ (1) NZ501165A (id)
PL (1) PL337925A1 (id)
PT (1) PT991424E (id)
RU (1) RU2216354C2 (id)
SK (1) SK122000A3 (id)
TR (1) TR199903026T2 (id)
UA (1) UA64761C2 (id)
WO (1) WO1999002189A1 (id)
ZA (1) ZA985993B (id)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6426341B1 (en) * 1999-06-30 2002-07-30 Pfizer Inc. Treatment for diabetic complications
AU2001238718A1 (en) * 2000-03-02 2001-09-12 The Institutes For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
US20080058424A1 (en) * 2002-05-23 2008-03-06 Cephalon, Inc. Novel pharmaceutical formulations of modafinil
WO2003013434A2 (en) * 2001-08-06 2003-02-20 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ace
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
AU2002352145A1 (en) * 2001-11-26 2003-06-10 Bayer Healthcare Ag Regulation of human aldose reductase-like protein
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
KR102051031B1 (ko) 2011-10-28 2019-12-02 루메나 파마수티컬즈, 인코포레이티드 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
BR112014010223B8 (pt) 2011-10-28 2021-02-23 Lumena Pharmaceuticals Llc uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
WO2014022291A1 (en) * 2012-07-28 2014-02-06 The Regents Of The University Of Colorado, A Body Corporate Compounds reducing the production of sorbitol in the eye and methods of using the same
CN103063794B (zh) * 2012-12-24 2014-08-06 扬子江药业集团南京海陵药业有限公司 一种依帕司他片的含量检测控制方法
CN115996725A (zh) * 2020-05-01 2023-04-21 应用治疗公司 用于治疗山梨糖醇脱氢酶缺乏症的醛糖还原酶抑制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9016978D0 (en) 1990-08-02 1990-09-19 Ici Plc Acetamide derivatives
AU711482B2 (en) * 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications

Also Published As

Publication number Publication date
HK1028876A1 (en) 2001-03-09
GB9714274D0 (en) 1997-09-10
AU8229698A (en) 1999-02-08
IL133004A (en) 2004-12-15
NO20000045L (no) 2000-01-06
PT991424E (pt) 2002-02-28
DE69801661T2 (de) 2002-07-04
CN1186097C (zh) 2005-01-26
AU746211B2 (en) 2002-04-18
TR199903026T2 (xx) 2000-04-21
CN1261804A (zh) 2000-08-02
UA64761C2 (uk) 2004-03-15
HU224009B1 (hu) 2005-04-28
BR9810570A (pt) 2000-09-19
IL133004A0 (en) 2001-03-19
DE69801661D1 (de) 2001-10-18
ES2163283T3 (es) 2002-01-16
JP2002509540A (ja) 2002-03-26
RU2216354C2 (ru) 2003-11-20
NZ501165A (en) 2001-06-29
ZA985993B (en) 1999-01-18
HUP0002644A2 (hu) 2000-12-28
US6337327B1 (en) 2002-01-08
CA2292451A1 (en) 1999-01-21
EP0991424A1 (en) 2000-04-12
EP0991424B1 (en) 2001-09-12
KR20010015551A (ko) 2001-02-26
CZ290276B6 (cs) 2002-06-12
PL337925A1 (en) 2000-09-11
WO1999002189A1 (en) 1999-01-21
DK0991424T3 (da) 2001-12-03
SK122000A3 (en) 2000-06-12
CZ200017A3 (cs) 2000-05-17
ATE205402T1 (de) 2001-09-15
NO20000045D0 (no) 2000-01-06

Similar Documents

Publication Publication Date Title
GB9714274D0 (en) Pharmaceutical composition
WO2003088931A3 (en) Polymeric odor absorption ingredients for personal care products
TR200001451T2 (tr) Aldoz redüktaz önleyici ve glikojen fosforilaz önleyici kombinasyonu.
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
GB2396297B (en) A cosmetic or dermopharmaceutical composition comprising an enzyme which is insoluble in an aqueous medium, as well as its uses.
ES2157307T3 (es) Composicion topica que contiene un antagonista de sustancia p.
KR970064594A (ko) 노화방지용 화장품 조성물
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
AU2002256093A1 (en) Bulking agents as satiety agents
NO20052690L (no) Fenylalaninderivater som dipeptidylpeptidaseinhibitorer for behandlingen eller profylaksen av sukkersyke.
EP1385508A4 (en) DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
PL366579A1 (en) Treatment of nail infections with no
MY138289A (en) Pharmaceutical compositions
AR004089A1 (es) Utilizacion de un antagonista de substancia p en una composicion topica , como agente antitranspirante.
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
PT1032414E (pt) Combinacao de um inibidor da enzima de conversao da angiotensina e de um diuretico para o tratamento de perturbacoes microcirculatorias
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
AU2003303076A1 (en) Cathepsin cysteine protease inhibitors and their use
IL124236A (en) Pharmaceutical composition for treating or reversing diabetic cardiomyopathy comprising aldose reductase inhibitor
AU7271300A (en) Particles for liquid compositions
BR0115983A (pt) Uso de sarp-1 para o tratamento e/ou prevenção de escleroderma
BR0011261B1 (pt) composiÇço oral compreendendo perlita, e, uso de perlita.
BR0111785A (pt) Composições e métodos para tratamento de candidìase
DE60041198D1 (de) Antimikrobielle zusammensetzungen
ATE405276T1 (de) Pharmazeutische gel-zusammensetzung